Skip to main content

CARMELINA confirms linagliptin’s renal, CV safety, but it’s still third-line for type 2 diabetes

Primary tabs

View
Get Stamp Tags
Published Locations

Breadcrumb

Home
CARMELINA confirms linagliptin’s renal, CV safety, but it’s still third-line for type 2 diabetes

User login

Username

Password

Reset your password

Type	Lead	score